Trials / Conditions / Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Stage IIIB Non-Small Cell Lung Cancer AJCC v7

11 registered clinical trials studyying Stage IIIB Non-Small Cell Lung Cancer AJCC v7.

Status	Trial	Sponsor	Phase
Terminated	Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer NCT03455556	Mayo Clinic	Phase 1
Withdrawn	CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer NCT03370159	Wake Forest University Health Sciences	Phase 1 / Phase 2
Terminated	Collection of Blood Samples in Patients With Non-small Cell Lung Cancer NCT03492801	University of Southern California	—
Completed	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278	Rutgers, The State University of New Jersey	Phase 1
Terminated	Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung NCT02846792	University of Washington	Phase 1 / Phase 2
Completed	Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lun NCT02503358	OHSU Knight Cancer Institute	Phase 1
Terminated	Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma NCT02408016	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer NCT01993810	Radiation Therapy Oncology Group	Phase 3
Terminated	Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small NCT01822496	National Cancer Institute (NCI)	Phase 2
Completed	Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Can NCT01727076	National Cancer Institute (NCI)	Phase 1
Completed	Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small NCT00698815	National Cancer Institute (NCI)	Phase 2